Skip to main content

Table 1 Baseline characteristics of the patients

From: Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

  Everolimus (n = 520) Sorafenib (n = 240) Sunitinib (n = 228) p-value*
Gender, n (%)
 Male 392 (75.4) 179 (74.6) 169 (74.1) 0.914
 Female 128 (24.6) 61 (25.4) 59 (25.9)  
Age at diagnosis [years]
 Median (range) 60 (33–81) 57 (33–78) 60 (33–80) 0.009
Metastatic disease, n (%)
 Metachronous 264 (55.8) 105 (49.5) 85 (42.7) 0.007
 Synchronous 209 (44.2) 107 (50.5) 114 (57.3)  
 Unknown 47 28 29  
Histology, n (%)
 Clear-cell carcinoma 490 (94.2) 227 (94.6) 213 (93.4) 0.938
 Papillary carcinoma 25 (4.8) 10 (4.2) 13 (5.7)  
 Other 5 (1.0) 3 (1.3) 2 (0.9)  
MSKCCa 520 (100.0) 240 (100.0) 228 (100.0) 0.058
 Good prognosis 185 (35.6) 89 (37.1) 87 (38.2)  
 Intermediate prognosis 316 (60.8) 135 (56.3) 122 (53.5)  
 Poor prognosis 19 (3.7) 16 (6.7) 19 (8.3)  
Previous nephrectomy, n (%) 444 (85.4) 216 (90.0) 189 (82.9) 0.072
Previous cytokines, n (%) 180 (34.6) 158 (65.8) 134 (58.8) < 0.001
Age at onset of second-line therapy [years]
 Median (range) 65 (37–83) 62 (35–83) 62 (34–82) < 0.001
ECOG PS at onset of second-line therapy, n (%)
 0 109 (27.8) 37 (21.5) 36 (23.7) 0.084
 1 265 (67.6) 117 (68.0) 105 (69.1)  
 2 17 (4.3) 18 (10.5) 11 (7.2)  
 3 1 (0.3) 0 (0.0) 0 (0.0)  
 Unknown 128 68 76  
Reason for treatment discontinuation, n (%)
 Progression or death 349 (78.3) 177 (76.3) 151 (72.9)
 Adverse event 33 (7.4) 28 (12.1) 32 (15.5)  
 Other 64 (14.3) 27 (11.6) 24 (11.6)  
Treatment duration [months]
 Mean (25–75 percentile) 6.1 (2.7–8.6) 7.1 (2.1–8.0) 7.1 (2.6–9.7)
Third-line targeted therapy, n (%) 79 (15.2) 80 (33.3) 61 (26.8)
Fourth-line targeted therapy, n (%) 2 (0.4) 3 (1.3) 4 (1.8)
  1. MSKCC Memorial Sloan Kettering Cancer Center, ECOG PS performance status according to Eastern Cooperative Oncology Group
  2. *Fisher exact test or Kruskal-Wallis test
  3. aMSKCC score calculated at the start of first-line therapy